

# Datasheet: MCA2235FA

**BATCH NUMBER 1804**

<b>Description:</b>	RAT ANTI MOUSE CD206:FITC
<b>Specificity:</b>	CD206
<b>Other names:</b>	MANNOSE RECEPTOR C TYPE 1
<b>Format:</b>	FITC
<b>Product Type:</b>	Monoclonal Antibody
<b>Clone:</b>	MR5D3
<b>Isotype:</b>	IgG2a
<b>Quantity:</b>	50 µg

## Product Details

### Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit [www.bio-rad-antibodies.com/protocols](http://www.bio-rad-antibodies.com/protocols).

	Yes	No	Not Determined	Suggested Dilution
Flow Cytometry (1)	▪			neat

Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use their own system using appropriate negative/positive controls.

**(1) CD206 is expressed weakly at the cell surface. Staining may be increased following membrane permeabilisation. Bio-Rad recommends the use of Leucoperm™ (Product Code [BUF09](#)) for this purpose.**

Target Species	Mouse		
Product Form	Purified IgG conjugated to Fluorescein Isothiocyanate Isomer 1 (FITC) - liquid		
Max Ex/Em	Fluorophore	Excitation Max (nm)	Emission Max (nm)
	FITC	490	525
Preparation	Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant		
Buffer Solution	Phosphate buffered saline		
Preservative	0.09% Sodium Azide		

Stabilisers	1% Bovine Serum Albumin
Approx. Protein Concentrations	IgG concentration 0.1 mg/ml
Immunogen	Chimaeric CRD4-7-Fc protein
External Database Links	<p><b>UniProt:</b>  <a href="#">Q61830</a>    <a href="#">Related reagents</a></p> <p><b>Entrez Gene:</b>  <a href="#">17533</a>    Mrc1    <a href="#">Related reagents</a></p>
RRID	AB_566630
Fusion Partners	Spleen cells from immunised Fischer rats were fused with cells of the Y3 myeloma cell line
Specificity	<p><b>Rat anti mouse CD206 antibody, clone MR5D3</b> recognizes the mouse mannose receptor, a ~175 kDa type 1 membrane glycoprotein that is also known as CD206. CD206 is expressed on most tissue macrophages, certain endothelial cells and <i>in vitro</i> derived dendritic cells (<a href="#">Zamze et al. 2002</a>).</p> <p>The mannose receptor, CD206, is composed of a N-terminal cysteine-rich domain, a fibronectin type II domain, eight tandemly arranged C-type lectin domains (CTLD), a transmembrane domain, and a cytoplasmic domain. The terminal cysteine-rich domain binds sulfated sugars, and the CTLD recognizes carbohydrates terminating in mannose, fucose and N-acetylglucosamine, all sugars found on microorganisms and on some endogenous proteins (<a href="#">Su et al. 2005</a>).</p> <p>Rat anti mouse CD206 antibody, clone MR5D3 has been reported to be non-inhibitory for the binding of the mannose receptor to carbohydrate ligands (<a href="#">Zamze et al. 2002</a>). Clone MR5D3 has also been shown to work in western blotting (<a href="#">Martinez-Pomares et al. 2003</a> and <a href="#">Su et al. 2005</a>).</p>
Flow Cytometry	<p>Use 10ul of the suggested working dilution to label 10<sup>6</sup> cells in 100ul.</p> <p>The Fc region of monoclonal antibodies may bind non-specifically to cells expressing low affinity Fc receptors. This may be reduced by using SeroBlock FcR (<a href="#">BUF041A/B</a>).</p>
References	<ol style="list-style-type: none"> <li>1. Martinez-Pomares, L. <i>et al.</i> (2003) Analysis of mannose receptor regulation by IL-4, IL-10, and proteolytic processing using novel monoclonal antibodies. <a href="#">J Leukoc Biol. 73 (5): 604-13.</a></li> <li>2. Nair, M.G. <i>et al.</i> (2009) Alternatively activated macrophage-derived RELM-<math>\alpha</math> is a negative regulator of type 2 inflammation in the lung. <a href="#">J Exp Med. 206: 937-52.</a></li> <li>3. Hassan, M.F. <i>et al.</i> (2006) The <i>Schistosoma mansoni</i> hepatic egg granuloma provides a favorable microenvironment for sustained growth of <i>Leishmania donovani</i>. <a href="#">Am J Pathol.</a></li> </ol>

[169: 943-53.](#)

4. Hardison, S.E. *et al.* (2010) Interleukin-17 Is Not Required for Classical Macrophage Activation in a Pulmonary Mouse Model of *Cryptococcus neoformans* Infection. [Infect Immun. 78: 5341-51.](#)
5. Geier, H. & Celli, J. (2011) Phagocytic receptors dictate phagosomal escape and intracellular proliferation of *Francisella tularensis*. [Infect Immun. 79 \(6\): 2204-14.](#)
6. Bacci, M. *et al.* (2009) Macrophages are alternatively activated in patients with endometriosis and required for growth and vascularization of lesions in a mouse model of disease. [Am J Pathol. 175: 547-56.](#)
7. Chavele, K.M. *et al.* (2010) Mannose receptor interacts with Fc receptors and is critical for the development of crescentic glomerulonephritis in mice. [J Clin Invest. 120: 1469-78.](#)
8. deSchoolmeester, M.L. *et al.* (2009) The mannose receptor binds *Trichuris muris* excretory/secretory proteins but is not essential for protective immunity. [Immunology 126: 246-55.](#)
9. Devey, L. *et al.* (2009) Tissue-resident macrophages protect the liver from ischemia reperfusion injury via a heme oxygenase-1-dependent mechanism. [Mol Ther. 17: 65-72.](#)
10. Dewals, B.G. *et al.* (2010) IL-4Ralpha-independent expression of mannose receptor and Ym1 by macrophages depends on their IL-10 responsiveness. [PLoS Negl Trop Dis. 4 \(5\): e689.](#)
11. Hardison, S.E. *et al.* (2010) Pulmonary infection with an interferon-gamma-producing *Cryptococcus neoformans* strain results in classical macrophage activation and protection. [Am J Pathol. 176: 774-85.](#)
12. Hawkes, C.A. *et al.* (2009) Selective targeting of perivascular macrophages for clearance of beta-amyloid in cerebral amyloid angiopathy. [Proc Natl Acad Sci USA 106: 1261-6.](#)
13. Zehner, M. *et al.* (2011) Mannose receptor polyubiquitination regulates endosomal recruitment of p97 and cytosolic antigen translocation for cross-presentation. [Proc Natl Acad Sci USA 108: 9933-8.](#)
14. Famulski, K.S. *et al.* (2010) Alternative macrophage activation-associated transcripts in T-cell-mediated rejection of mouse kidney allografts. [Am J Transplant 10 \(3\): 490-7.](#)
15. Takagi, H. *et al.* (2009) Cooperation of specific ICAM-3 grabbing nonintegrin-related 1 (SIGNR1) and complement receptor type 3 (CR3) in the uptake of oligomannose-coated liposomes by macrophages. [Glycobiology 19: 258-66.](#)
16. Deepe, G.S. Jr. & Buesing, W.R. (2011) Deciphering the Pathways of Death of *Histoplasma capsulatum*-Infected Macrophages: Implications for the Immunopathogenesis of Early Infection. [J Immunol. 188: 334-44.](#)
17. Schneider, D. *et al.* (2012) Neonatal rhinovirus infection induces mucous metaplasia and airways hyperresponsiveness. [J Immunol. 188 \(6\): 2894-904.](#)
18. Kondo, Y. *et al.* (2011) Macrophages counteract demyelination in a mouse model of globoid cell leukodystrophy. [J Neurosci. 31: 3610-24.](#)
19. Joyce, K.L. *et al.* (2012) Using eggs from *Schistosoma mansoni* as an *in vivo* model of helminth-induced lung inflammation. [J Vis Exp. Jun 5 \(64\): e3905.](#)
20. Su, Y. *et al.* (2005) Glycosylation influences the lectin activities of the macrophage mannose receptor. [J Biol Chem. 280: 32811-20.](#)
21. Verheijden, S. *et al.* (2015) Identification of a chronic non-neurodegenerative microglia activation state in a mouse model of peroxisomal  $\beta$ -oxidation deficiency. [Glia. 63 \(9\): 1606-20.](#)

22. O'Flaherty, B.M. *et al.* (2015) CD8+ T Cell Response to Gammaherpesvirus Infection Mediates Inflammation and Fibrosis in Interferon Gamma Receptor-Deficient Mice. [PLoS One. 10 \(8\): e0135719.](#)
23. Eßlinger M *et al.* (2016) Schizophrenia associated sensory gating deficits develop after adolescent microglia activation. [Brain Behav Immun. 58: 99-106.](#)
24. Øie, C.I. *et al.* (2016) FITC Conjugation Markedly Enhances Hepatic Clearance of N-Formyl Peptides. [PLoS One. 11 \(8\): e0160602.](#)
25. Manning, C.N. *et al.* (2015) Adipose-derived mesenchymal stromal cells modulate tendon fibroblast responses to macrophage-induced inflammation *in vitro*. [Stem Cell Res Ther. 6: 74.](#)
26. Sindrilaru, A. *et al.* (2011) An unrestrained proinflammatory M1 macrophage population induced by iron impairs wound healing in humans and mice. [J Clin Invest. 121: 985-97.](#)
27. Bongiorno, E.K. *et al.* (2017) Type 1 Immune Mechanisms Driven by the Response to Infection with Attenuated Rabies Virus Result in Changes in the Immune Bias of the Tumor Microenvironment and Necrosis of Mouse GL261 Brain Tumors. [J Immunol. 198 \(11\): 4513-23.](#)
28. Braune, J. *et al.* (2017) IL-6 Regulates M2 Polarization and Local Proliferation of Adipose Tissue Macrophages in Obesity. [J Immunol. 198 \(7\): 2927-34.](#)
29. Litvack ML *et al.* (2016) Alveolar-like Stem Cell-derived Myb(-) Macrophages Promote Recovery and Survival in Airway Disease. [Am J Respir Crit Care Med. 193 \(11\): 1219-29.](#)
30. Sameshima, A. *et al.* (2015) Teneligliptin improves metabolic abnormalities in a mouse model of postmenopausal obesity. [J Endocrinol. 227 \(1\): 25-36.](#)
31. Eskilsson, A. *et al.* (2014) Distribution of microsomal prostaglandin E synthase-1 in the mouse brain. [J Comp Neurol. 522 \(14\): 3229-44.](#)
32. Hosono, K. *et al.* (2016) Signaling of Prostaglandin E Receptors, EP3 and EP4 Facilitates Wound Healing and Lymphangiogenesis with Enhanced Recruitment of M2 Macrophages in Mice. [PLoS One. 11 \(10\): e0162532.](#)
33. Han, Y.H. *et al.* (2019) A maresin 1/ROR $\alpha$ /12-lipoxygenase autoregulatory circuit prevents inflammation and progression of nonalcoholic steatohepatitis. [J Clin Invest. 130. pii: 124219](#)
34. Rahman, K. *et al.* (2017) Inflammatory Ly6Chi monocytes and their conversion to M2 macrophages drive atherosclerosis regression. [J Clin Invest. 127 \(8\): 2904-2915.](#)
35. Qiao, X. *et al.* (2020) Magnesium-doped Nanostructured Titanium Surface Modulates Macrophage-mediated Inflammatory Response for Ameliorative Osseointegration. [Int J Nanomedicine. 15: 7185-98.](#)
36. Shiau, D.J. *et al.* (2020) Hepatocellular carcinoma-derived high mobility group box 1 triggers M2 macrophage polarization via a TLR2/NOX2/autophagy axis. [Sci Rep. 10 \(1\): 13582.](#)
37. Fan, A. *et al.* (2020) High-salt diet decreases mechanical thresholds in mice that is mediated by a CCR2-dependent mechanism. [J Neuroinflammation. 17 \(1\): 179.](#)
38. Kalovyryna, N. *et al.* (2020) A 3'UTR modification of the TNF- $\alpha$  mouse gene increases peripheral TNF- $\alpha$  and modulates the Alzheimer-like phenotype in 5XFAD mice. [Sci Rep. 10 \(1\): 8670.](#)
39. Kishimoto, S. *et al.* (2020) Surgical Injury and Ischemia Prime the Adipose Stromal Vascular Fraction and Increase Angiogenic Capacity in a Mouse Limb Ischemia Model. [Stem Cells Int. 2020: 7219149.](#)

40. Espagnol, N. *et al.* (2014) Specific Inhibition of the VEGFR-3 Tyrosine Kinase by SAR131675 Reduces Peripheral and Tumor Associated Immunosuppressive Myeloid Cells. [Cancers \(Basel\). 6 \(1\): 472-90.](#)
41. Fridlender, Z.G. *et al.* (2013) Using macrophage activation to augment immunotherapy of established tumours. [Br J Cancer. 108 \(6\): 1288-97.](#)

<b>Storage</b>	Store at +4°C or at -20°C if preferred.  This product should be stored undiluted.  Storage in frost-free freezers is not recommended. This product is photosensitive and should be protected from light.  Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
<b>Guarantee</b>	12 months from date of despatch
<b>Health And Safety Information</b>	Material Safety Datasheet documentation #10041 available at: <a href="https://www.bio-rad-antibodies.com/SDS/MCA2235FA">https://www.bio-rad-antibodies.com/SDS/MCA2235FA</a> 10041
<b>Regulatory</b>	For research purposes only

## Related Products

### Recommended Negative Controls

[RAT IgG2a NEGATIVE CONTROL:FITC \(MCA1212F\)](#)

<b>North &amp; South America</b>	Tel: +1 800 265 7376 Fax: +1 919 878 3751 Email: <a href="mailto:antibody_sales_us@bio-rad.com">antibody_sales_us@bio-rad.com</a>	<b>Worldwide</b>	Tel: +44 (0)1865 852 700 Fax: +44 (0)1865 852 739 Email: <a href="mailto:antibody_sales_uk@bio-rad.com">antibody_sales_uk@bio-rad.com</a>	<b>Europe</b>	Tel: +49 (0) 89 8090 95 21 Fax: +49 (0) 89 8090 95 50 Email: <a href="mailto:antibody_sales_de@bio-rad.com">antibody_sales_de@bio-rad.com</a>
----------------------------------	---	------------------	---	---------------	---

To find a batch/lot specific datasheet for this product, please use our online search tool at: [bio-rad-antibodies.com/datasheets](https://www.bio-rad-antibodies.com/datasheets)  
'M366394:200529'

Printed on 21 Mar 2024